Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma
Recent Articles
Trump to Nominate Stephen Hahn as FDA Commissioner
President Donald Trump is set to nominate Stephen Hahn, MD, as U.S. Food and Drug Administration (FDA) commissioner, pending the completion of his vetting...
FDA Warns of Cybersecurity Vulnerabilities in Medical Devices
The U.S. Food and Drug Administration (FDA) has warned patients, providers, and medical device manufacturers about possible cybersecurity liabilities in certain medical devices and...
Trump Administration Renews Efforts to Dismantle the Affordable Care Act
When it was introduced nearly 10 years ago, the primary objective of the Patient Protection and Affordable Care Act (ACA) was to provide more...
Nobel Prize Awarded for Discovery of How Cells Sense Oxygen
The Nobel Prize in physiology or medicine was awarded to scientists William G. Kaelin Jr., MD, Peter J. Ratcliffe, FRS, FMedSci, and Gregg L....
U.K. Labour Party Plans to Regulate Pharmaceutical Market, Lower Drug Prices
The U.K. Labour Party has pledged to reform the country’s pharmaceutical market by establishing a publicly owned generic drug manufacturer and expanding the government’s...
Current Issue
October 2019, Volume 5, Issue 12
This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.
